Medtronic PLC $MDT Stock Holdings Boosted by HB Wealth Management LLC

HB Wealth Management LLC boosted its position in Medtronic PLC (NYSE:MDT) by 7.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 108,625 shares of the medical technology company’s stock after purchasing an additional 7,356 shares during the quarter. HB Wealth Management LLC’s holdings in Medtronic were worth $10,346,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Medtronic during the second quarter worth approximately $1,432,698,000. Vanguard Group Inc. increased its position in Medtronic by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock valued at $11,062,693,000 after acquiring an additional 1,895,165 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Medtronic by 332.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,494,782 shares of the medical technology company’s stock valued at $130,300,000 after acquiring an additional 1,148,803 shares in the last quarter. Perkins Coie Trust Co boosted its position in Medtronic by 2,952.2% during the 2nd quarter. Perkins Coie Trust Co now owns 1,155,425 shares of the medical technology company’s stock worth $100,718,000 after acquiring an additional 1,117,570 shares during the period. Finally, Laurel Wealth Advisors LLC grew its stake in shares of Medtronic by 8,779.8% in the second quarter. Laurel Wealth Advisors LLC now owns 1,069,664 shares of the medical technology company’s stock worth $93,243,000 after purchasing an additional 1,057,618 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 1.0%

NYSE MDT opened at $98.78 on Friday. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The company has a market capitalization of $126.64 billion, a P/E ratio of 26.63, a PEG ratio of 2.63 and a beta of 0.71. The company’s 50 day simple moving average is $98.17 and its 200 day simple moving average is $94.37. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s payout ratio is 76.55%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on MDT. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, January 3rd. Leerink Partners set a $120.00 price target on shares of Medtronic and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Stifel Nicolaus increased their price objective on shares of Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Cowen reiterated a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Finally, Wells Fargo & Company upped their target price on Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $110.22.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).